- Home
- DVAX vs KZR Comparison
DVAX vs KZR Comparison
Compare DVAX & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- KZR
- Stock Information
- Founded
- DVAX 1996
- KZR 2015
- Country
- DVAX United States
- KZR United States
- Employees
- DVAX N/A
- KZR N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- KZR Health Care
- Exchange
- DVAX Nasdaq
- KZR Nasdaq
- Market Cap
- DVAX 1.3B
- KZR 29.7M
- IPO Year
- DVAX 2004
- KZR 2018
- Fundamental
- Price
- DVAX $9.25
- KZR $3.90
- Analyst Decision
- DVAX Buy
- KZR Hold
- Analyst Count
- DVAX 4
- KZR 2
- Target Price
- DVAX $26.50
- KZR $9.00
- AVG Volume (30 Days)
- DVAX 1.9M
- KZR 35.9K
- Earning Date
- DVAX 11-06-2025
- KZR 11-11-2025
- Dividend Yield
- DVAX N/A
- KZR N/A
- EPS Growth
- DVAX N/A
- KZR N/A
- EPS
- DVAX N/A
- KZR N/A
- Revenue
- DVAX $316,268,000.00
- KZR N/A
- Revenue This Year
- DVAX $23.23
- KZR N/A
- Revenue Next Year
- DVAX $16.57
- KZR N/A
- P/E Ratio
- DVAX N/A
- KZR N/A
- Revenue Growth
- DVAX 26.66
- KZR N/A
- 52 Week Low
- DVAX $9.22
- KZR $3.62
- 52 Week High
- DVAX $14.63
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- DVAX 31.91
- KZR 46.16
- Support Level
- DVAX $9.51
- KZR $3.93
- Resistance Level
- DVAX $9.94
- KZR $4.09
- Average True Range (ATR)
- DVAX 0.28
- KZR 0.13
- MACD
- DVAX -0.08
- KZR 0.02
- Stochastic Oscillator
- DVAX 0.91
- KZR 48.72
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.